{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T13:28:20Z","timestamp":1768656500697,"version":"3.49.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T00:00:00Z","timestamp":1641772800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1007\/s10620-021-07362-y","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T09:02:32Z","timestamp":1641805352000},"page":"4687-4694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Appropriateness of Medical and Surgical Treatments for Chronic Pouchitis Using RAND\/UCLA Appropriateness Methodology"],"prefix":"10.1007","volume":"67","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5803-5877","authenticated-orcid":false,"given":"Gaurav","family":"Syal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles P.","family":"Sparrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Velayos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Cheifetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shane","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilaad G.","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Raffals","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ullman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krisztina B.","family":"Gecse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip R.","family":"Fleshner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy L.","family":"Lightner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corey A.","family":"Siegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil Y.","family":"Melmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,1,10]]},"reference":[{"key":"7362_CR1","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1093\/ecco-jcc\/jjy040","volume":"12","author":"L Parragi","year":"2018","unstructured":"Parragi L, Fournier N, Zeitz J et al. Colectomy rates in ulcerative colitis are low and decreasing: 10-year follow-up data from the swiss IBD cohort study. J Crohns Colitis. 2018;12:811\u2013818. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjy040.","journal-title":"J Crohns Colitis."},{"key":"7362_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa232","author":"IL Monstad","year":"2020","unstructured":"Monstad IL, Solberg IC, Cvancarova M et al. Outcome of Ulcerative Colitis 20 Years after Diagnosis in a Prospective Population-based Inception Cohort from South-Eastern Norway, the IBSEN Study. J Crohns Colitis. 2020. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa232.","journal-title":"J Crohns Colitis"},{"key":"7362_CR3","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2013.07.041","volume":"145","author":"AD Frolkis","year":"2013","unstructured":"Frolkis AD, Dykeman J, Negr\u00f3n ME et al. Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology 2013;145:996\u20131006. https:\/\/doi.org\/10.1053\/j.gastro.2013.07.041.","journal-title":"Gastroenterology"},{"key":"7362_CR4","doi-asserted-by":"publisher","unstructured":"Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016;44: 807\u2013816. https:\/\/doi.org\/10.1111\/apt.13763","DOI":"10.1111\/apt.13763"},{"key":"7362_CR5","doi-asserted-by":"publisher","unstructured":"Barnes EL, Herfarth HH, Kappelman MD, et al. Incidence, risk factors, and outcomes of pouchitis and pouch-related complications in patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2021;19:1583\u20131591.e4. https:\/\/doi.org\/10.1016\/j.cgh.2020.06.035","DOI":"10.1016\/j.cgh.2020.06.035"},{"key":"7362_CR6","doi-asserted-by":"publisher","unstructured":"Lightner AL, Mathis KL, Dozois EJ, et al. Results at up to 30 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Inflamm Bowel Dis. 2017;23:781\u2013790. https:\/\/doi.org\/10.1097\/MIB.0000000000001061","DOI":"10.1097\/MIB.0000000000001061"},{"key":"7362_CR7","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1097\/SLA.0b013e31827d99a2","volume":"257","author":"VW Fazio","year":"2013","unstructured":"Fazio VW, Kiran RP, Remzi FH et al. Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg. 2013;257:679\u2013685. https:\/\/doi.org\/10.1097\/SLA.0b013e31827d99a2.","journal-title":"Ann Surg."},{"key":"7362_CR8","first-page":"334","volume":"46","author":"TE Madiba","year":"2001","unstructured":"Madiba TE, Bartolo DC. Pouchitis following restorative proctocolectomy for ulcerative colitis: incidence and therapeutic outcome. J R Coll Surg Edinb. 2001;46:334\u2013337.","journal-title":"J R Coll Surg Edinb."},{"key":"7362_CR9","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz227","author":"M Kayal","year":"2019","unstructured":"Kayal M, Plietz M, Rizvi A et al. Inflammatory pouch conditions are common after ileal pouch anal anastomosis in ulcerative colitis patients. Inflamm Bowel Dis. 2019. https:\/\/doi.org\/10.1093\/ibd\/izz227.","journal-title":"Inflamm Bowel Dis."},{"key":"7362_CR10","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00384-013-1814-6","volume":"29","author":"S Koerdt","year":"2014","unstructured":"Koerdt S, Jehle EC, Kreis ME, Kasparek MS. Quality of life after proctocolectomy and ileal pouch-anal anastomosis in patients with ulcerative colitis. Int J Colorectal Dis. 2014;29:545\u2013554. https:\/\/doi.org\/10.1007\/s00384-013-1814-6.","journal-title":"Int J Colorectal Dis."},{"key":"7362_CR11","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s003840050069","volume":"12","author":"S K\u00f6rsgen","year":"1997","unstructured":"K\u00f6rsgen S, Keighley MR. Causes of failure and life expectancy of the ileoanal pouch. Int J Colorectal Dis. 1997;12:4\u20138. https:\/\/doi.org\/10.1007\/s003840050069.","journal-title":"Int J Colorectal Dis."},{"key":"7362_CR12","doi-asserted-by":"publisher","unstructured":"Papamichael K, Cheifetz AS, Melmed GY, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655\u20131668. https:\/\/doi.org\/10.1016\/j.cgh.2019.03.037","DOI":"10.1016\/j.cgh.2019.03.037"},{"key":"7362_CR13","doi-asserted-by":"publisher","unstructured":"Melmed GY, Kaplan GG, Sparrow MP, et al. Appropriateness of combination therapy for patients with inflammatory bowel diseases: one size still does not fit all. Clin Gastroenterol Hepatol. 2018;16:1829\u20131831. https:\/\/doi.org\/10.1016\/j.cgh.2018.02.036","DOI":"10.1016\/j.cgh.2018.02.036"},{"key":"7362_CR14","doi-asserted-by":"publisher","unstructured":"Melmed GY, Irving PM, Jones J, et al. Appropriateness of testing for anti-tumor necrosis factor agent and antibody concentrations, and interpretation of\u00a0results. Clin Gastroenterol Hepatol. 2016;14:1302\u20139. https:\/\/doi.org\/10.1016\/j.cgh.2016.05.010","DOI":"10.1016\/j.cgh.2016.05.010"},{"key":"7362_CR15","doi-asserted-by":"publisher","unstructured":"Devlin SM, Melmed GY, Irving PM, et al. Recommendations for quality colonoscopy reporting for patients with inflammatory bowel disease: results from a RAND appropriateness panel. Inflamm Bowel Dis. 2016;22:1418\u201324. https:\/\/doi.org\/10.1097\/MIB.0000000000000764","DOI":"10.1097\/MIB.0000000000000764"},{"key":"7362_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjaa251","author":"G Syal","year":"2020","unstructured":"Syal G, Shemtov R, Bonthala N et al. Pre-pouch ileitis is associated with development of crohn\u2019s disease-like complications and pouch failure. J Crohns Colitis. 2020. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa251.","journal-title":"J Crohns Colitis."},{"key":"7362_CR17","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.cgh.2013.03.033","volume":"11","author":"B Shen","year":"2013","unstructured":"Shen B. Pouchitis: what every gastroenterologist needs to know. Clin Gastroenterol Hepatol. 2013;11:1538\u20131549. https:\/\/doi.org\/10.1016\/j.cgh.2013.03.033.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7362_CR18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1136\/flgastro-2017-100913","volume":"9","author":"JP Segal","year":"2018","unstructured":"Segal JP, Poo SX, McLaughlin SD, Faiz OD, Clark SK, Hart AL. Long-term follow-up of the use of maintenance antibiotic therapy for chronic antibiotic-dependent pouchitis. Frontline Gastroenterol. 2018;9:154\u2013158. https:\/\/doi.org\/10.1136\/flgastro-2017-100913.","journal-title":"Frontline Gastroenterol."},{"key":"7362_CR19","doi-asserted-by":"publisher","unstructured":"Quinn KP, Raffals LE. An update on the medical management of inflammatory pouch complications. Am J Gastroenterol. 2020;115:1439\u20131450. https:\/\/doi.org\/10.14309\/ajg.0000000000000666","DOI":"10.14309\/ajg.0000000000000666"},{"key":"7362_CR20","unstructured":"Accessed March 7, 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/019537s082,020780s040lbl.pdf"},{"key":"7362_CR21","doi-asserted-by":"publisher","unstructured":"Huguet M, Pereira B, Goutte M, et al. Systematic review with meta-analysis: anti-tnf therapy in refractory pouchitis and crohn's disease-like complications of the pouch after ileal pouch-anal anastomosis following colectomy for ulcerative colitis. Inflamm Bowel Dis. 2018;24:261\u2013268. https:\/\/doi.org\/10.1093\/ibd\/izx049","DOI":"10.1093\/ibd\/izx049"},{"key":"7362_CR22","doi-asserted-by":"publisher","unstructured":"Weaver KN, Gregory M, Syal G, et al. Ustekinumab is effective for the treatment of crohn's disease of the pouch in a multicenter cohort. Inflamm Bowel Dis. 2019;25:767\u2013774. https:\/\/doi.org\/10.1093\/ibd\/izy302","DOI":"10.1093\/ibd\/izy302"},{"key":"7362_CR23","doi-asserted-by":"publisher","unstructured":"Gregory M, Weaver KN, Hoversten P, et al. Efficacy of Vedolizumab for Refractory Pouchitis of the Ileo-anal Pouch: Results From a Multicenter US Cohort. Inflamm Bowel Dis. 2019;25:1569\u20131576. https:\/\/doi.org\/10.1093\/ibd\/izz030","DOI":"10.1093\/ibd\/izz030"},{"key":"7362_CR24","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1111\/apt.12440","volume":"38","author":"T Nunes","year":"2013","unstructured":"Nunes T, Etchevers MJ, Dom\u00e8nech E et al. Smoking does influence disease behaviour and impacts the need for therapy in Crohn\u2019s disease in the biologic era. Aliment Pharmacol Ther. 2013;38:752\u2013760. https:\/\/doi.org\/10.1111\/apt.12440.","journal-title":"Aliment Pharmacol Ther."},{"key":"7362_CR25","doi-asserted-by":"publisher","unstructured":"Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of crohn's disease in adults. Am J Gastroenterol. 2018;113:481\u2013517. https:\/\/doi.org\/10.1038\/ajg.2018.27","DOI":"10.1038\/ajg.2018.27"},{"key":"7362_CR26","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1093\/ecco-jcc\/jjz180","volume":"14","author":"J Torres","year":"2020","unstructured":"Torres J, Bonovas S, Doherty G et al. ECCO guidelines on therapeutics in crohn\u2019s disease: medical treatment. J Crohns Colitis. 2020;14:4\u201322. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjz180.","journal-title":"J Crohns Colitis."},{"key":"7362_CR27","doi-asserted-by":"publisher","unstructured":"Feuerstein JD, Isaacs KL, Schneider Y, et al. AGA Clinical practice guidelines on the management of moderate to severe ulcerative colitis. Gastroenterology. 2020;158:1450\u20131461. https:\/\/doi.org\/10.1053\/j.gastro.2020.01.006","DOI":"10.1053\/j.gastro.2020.01.006"},{"key":"7362_CR28","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/ecco-jcc\/jjw134","volume":"11","author":"L Robbins","year":"2017","unstructured":"Robbins L, Zaghiyan K, Melmed G et al. Outcomes with anti-tumour necrosis factor-alpha therapy and serology in patients with denovo crohn\u2019s disease after ileal pouch anal anastomosis. J Crohns Colitis. 2017;11:77\u201383. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjw134.","journal-title":"J Crohns Colitis."},{"key":"7362_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.07.008","author":"M Kayal","year":"2020","unstructured":"Kayal M, Lambin T, Plietz M et al. Recycling of precolectomy anti-tumor necrosis factor agents in chronic pouch inflammation is associated with treatment failure. Clin Gastroenterol Hepatol. 2020. https:\/\/doi.org\/10.1016\/j.cgh.2020.07.008.","journal-title":"Clin Gastroenterol Hepatol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-021-07362-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-021-07362-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T18:18:10Z","timestamp":1664302690000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-021-07362-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,10]]},"references-count":29,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["7362"],"URL":"https:\/\/doi.org\/10.1007\/s10620-021-07362-y","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,10]]},"assertion":[{"value":"23 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Gaurav Syal has served as a consultant for Gilead and Prometheus Laboratories; speaker for HCPLive; and received research support from Pfizer. Miles P Sparrow has received educational grants or research support from Ferring, Orphan, and Gilead; speaker\u2019s fees from Janssen, Abbvie, Ferring, Takeda, Pfizer and Shire; and has served on advisory boards for Janssen, Takeda, Pfizer, Celgene, Abbvie, MSD, Emerge Health, and Gilead. Fernando Velayos has no relevant disclosures. Adam S Cheifetz has served as a consultant for Janssen, Abbvie, Takeda, Pfizer, Samsung, Arena, Bristol Myers Squibb, Prometheus, Bacainn, and Grifols and received research support from Inform Diagnostics. Shane Devlin has served as a speaker or consultant for Abbvie, Janssen, Takeda, Fresenius-Kabi, and Pfizer. Peter M Irving has served as a speaker or a consultant for AbbVie, Arena, Celgene, Ferring, Prometheus, Shire, Warner Chilcott, Takeda, MSD, Vifor Pharma, Pharmacosmos, Topivert, Gilead, Galapagos, BMS, Genentech, Hospira, Samsung Bioepis, VH2, Janssen, Sandoz, and Lilly, Roche; and has received research support from MSD, Pfizer, and Takeda<b>.<\/b> Gilaad G Kaplan served as a speaker or a consultant for Abbvie, Janssen, Pfizer, Amgen, Gilead, and Takeda; received research support from Ferring, Janssen, Abbvie, Glaxo-Smith Kline, Merck, and Shire; and shares ownership of a patent: TREATMENT OF INFLAMMATORY DISORDERS, AUTOIMMUNE DISEASE, AND PBC. UTI Limited Partnership, assignee. Patent WO2019046959A1. PCT\/CA2018\/051098. 7 Sept. 2018. Laura Raffals has no relevant disclosures. Thomas Ullman has no relevant disclosures. Krisztina B Gecse has received grants from Pfizer Inc. and Celltrion; consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc., Samsung Bioepis, and Takeda and speaker\u2019s honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda and Tillotts. Phillip R Fleshner has served as a consultant to Takeda. Amy L Lightner has served as a consultant to Takeda. Corey A Siegel has served as a consultant to Abbvie, BMS, Lilly, Janssen, Pfizer, Prometheus, Takeda, and Trellus Health; speaker for CME activities for Abbvie, Janssen, Pfizer, and Takeda; and received grant support from Abbvie, Janssen, Pfizer, and Takeda. Gil Y Melmed has served as a consultant to Abbvie, Arena, Boehringer-Ingelheim, Bristol-Meyer Squibb\/Celgene, Entasis, Janssen, Medtronic, Pfizer, Samsung Bioepis, Shionogi, Takeda, and TechLab and received research funding from Pfizer.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}